» Articles » PMID: 37568788

Innate Immune System in the Context of Radiation Therapy for Cancer

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Aug 12
PMID 37568788
Authors
Affiliations
Soon will be listed here.
Abstract

Radiation therapy (RT) remains an integral component of modern oncology care, with most cancer patients receiving radiation as a part of their treatment plan. The main goal of ionizing RT is to control the local tumor burden by inducing DNA damage and apoptosis within the tumor cells. The advancement in RT, including intensity-modulated RT (IMRT), stereotactic body RT (SBRT), image-guided RT, and proton therapy, have increased the efficacy of RT, equipping clinicians with techniques to ensure precise and safe administration of radiation doses to tumor cells. In this review, we present the technological advancement in various types of RT methods and highlight their clinical utility and associated limitations. This review provides insights into how RT modulates innate immune signaling and the key players involved in modulating innate immune responses, which have not been well documented earlier. Apoptosis of cancer cells following RT triggers immune systems that contribute to the eradication of tumors through innate and adoptive immunity. The innate immune system consists of various cell types, including macrophages, dendritic cells, and natural killer cells, which serve as key mediators of innate immunity in response to RT. This review will concentrate on the significance of the innate myeloid and lymphoid lineages in anti-tumorigenic processes triggered by RT. Furthermore, we will explore essential strategies to enhance RT efficacy. This review can serve as a platform for researchers to comprehend the clinical application and limitations of various RT methods and provides insights into how RT modulates innate immune signaling.

Citing Articles

Enhancing immunotherapy efficacy with synergistic low-dose radiation in metastatic melanoma: current insights and prospects.

Rafiq Z, Kang M, Barsoumian H, Manzar G, Hu Y, Leuschner C J Exp Clin Cancer Res. 2025; 44(1):31.

PMID: 39881333 PMC: 11781074. DOI: 10.1186/s13046-025-03281-2.


Results of an Integrated Phase I/II Prospective Clinical Trial (NEXIS) for Neoadjuvant Anti-PD-L1 (Durvalumab) and Anti-CTLA-4 (Tremelimumab) With Radiation for High-Risk Soft-Tissue Sarcoma of the Trunk and Extremities.

Ng V, Sahlani M, Fogel J, Chiu A, Kallen M, Davis D Cureus. 2024; 16(10):e72119.

PMID: 39575028 PMC: 11581454. DOI: 10.7759/cureus.72119.


Consensus, debate, and prospective on pancreatic cancer treatments.

Wang J, Yang J, Narang A, He J, Wolfgang C, Li K J Hematol Oncol. 2024; 17(1):92.

PMID: 39390609 PMC: 11468220. DOI: 10.1186/s13045-024-01613-x.


Therapeutic In Situ Cancer Vaccine Using Pulsed Stereotactic Body Radiotherapy-A Translational Model.

Swamy K Vaccines (Basel). 2024; 12(1).

PMID: 38276666 PMC: 10819354. DOI: 10.3390/vaccines12010007.

References
1.
Haynes D . The integrity of research published by Stephen E. Breuning. Bull Med Libr Assoc. 1988; 76(3):272. PMC: 227121. View

2.
Blasi A, DALFONSO G . [Respiratory system and environmental noxiousness]. Arch Monaldi Mal Torace. 1987; 42(1):7-23. View

3.
Rockwell S, Dobrucki I, Kim E, Marrison S, Vu V . Hypoxia and radiation therapy: past history, ongoing research, and future promise. Curr Mol Med. 2009; 9(4):442-58. PMC: 2752413. DOI: 10.2174/156652409788167087. View

4.
Ishihara H, Tanaka I, Nemoto K, TSUNEOKA K, Cheeramakara C, Yoshida K . Immediate-early, transient induction of the interleukin-1 beta gene in mouse spleen macrophages by ionizing radiation. J Radiat Res. 1995; 36(2):112-24. DOI: 10.1269/jrr.36.112. View

5.
Alizadeh E, Orlando T, Sanche L . Biomolecular damage induced by ionizing radiation: the direct and indirect effects of low-energy electrons on DNA. Annu Rev Phys Chem. 2015; 66:379-98. DOI: 10.1146/annurev-physchem-040513-103605. View